Revenue Update on Regenxbio Inc(NASDAQ:RGNX)

Regenxbio Inc(NASDAQ:RGNX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $2.38M. Analysts estimated a revenue of $1.98M. Earnings per share were $-0.55. Analysts had estimated an EPS of $-0.53.

REGENXBIO Inc. formerly ReGenX Biosciences LLC is a biotechnology company focused on the development commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s AAV gene delivery platform (its NAV technology platform) consists of exclusive rights to over 100 AAV vectors including AAV7 AAV8 AAV9 and AAVrh10 (NAV Vectors). The Company focuses on the lives of patients suffering from diseases with unmet medical needs by developing and commercializing gene therapy products administered directly into the body or in vivo based on its NAV technology platform. Its NAV technology platform is applied in the development of over 20 product candidates for a range of diseases including five product candidates and approximately 20 partnered product candidates developed by its NAV technology licensees. The Company’s products candidates include RGX-501 RGX-111 RGX-121 RGX-314 and RGX-321.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Regenxbio Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Regenxbio Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.